α-CD as laxative for pets and CD as litter deodorant
In present post, two Japanese products for pet care are discussed. The product characteristics quoted here reflect the information claimed
Author: István Puskás
research chemist
Bacteroides uniformis and its preferred substrate, α-cyclodextrin, enhance endurance exercise performance in mice and human males
A recent Japanese study revealed surprising enhanced sports endurance of human volunteers after long-term consumption of α-cyclodextrin. Oral intake of
Patent application on reduction of envelope viral particle number in a composition containing cyclodextrin
US patent application US2022409653 entitled “METHOD FOR PREVENTING ENTRY AND REPLICATION OF ENVELOPED VIRUSES” descibes a method for the reduction
Published compilation of the list of approved cyclodextrin-containing drug products
A group of researchers at CycloLab continuously follow the new drug composition approvals especially those benefiting the use of cyclodextrins.
New US patent for SBECD purification by CycloLab
The status of US patent application 17/344,217 (“Purification of sulfobutylated cyclodextrins with specific ion exchange resins” by CycloLab, Hungary) was
Remdesivir- Dexolve formulation in the space – a book of NASA
In the annual report of NASA there is a great recognition of benefits of cyclodextrin technology even in space chemistry.
Low sulfur biodiesel produced from sewage enabled by beta-cyclodextrin
Emeritus Professor Richard Parnas and his group at University of Connecticut Department of Chemical and Biomolecular Engineering developed a technology
May a novel alfa-cyclodextrin derivative be applied effectively to capture atmospheric methane?
Researchers at the University of Copenhagen’s Faculty of Science received a research grant to find out. Methane gas is 86
Nature.com: HPBCD treatment improves learning and executive function in Alzheimer model mice
Earlier we have reported on a patent appication related to HPBCD treatment in Alzheimer’s disease based on the invention of
First Patient Enrolled in Phase 1 Study of Midatech’s Panobinostat / HPBCD (MTX-110) for Recurrent Glioblastoma
Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announced on 14 November